PatientsVille.com Logo


Malocide Medical Research Studies

Up-to-date List of Malocide Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Malocide Medical Research Studies

Rank Status Study
1 Recruiting Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Leukemia
Intervention: Drug: pyrimethamine
Outcome Measures: Phase I: To determine the maximum tolerated dose and recommended Phase 2 dose of pyrimethamine in relapsed CLL/SLL;   Phase II: To determine the overall response rate of pyrimethamine in relapsed CLL/SLL.;   To assess the toxicity profile of pyrimethamine in relapsed CLL/SLL, both acutely and over prolonged daily dosing.;   To determine pyrimethamine levels in vivo with prolonged dosing.;   To determine the progression-free survival following pyrimethamine for the treatment of relapsed CLL/SLL
2 Recruiting Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy
Condition: Congenital Toxoplasmosis
Interventions: Drug: Pyrimethamine/Sulfadiazine;   Drug: Spiramycine
Outcome Measures: Rate of mother-to-child transmission;   Secondary Outcome Measure
3 Recruiting Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Condition: Toxoplasmosis
Interventions: Drug: Leucovorin calcium;   Drug: Pyrimethamine;   Drug: Spiramycin;   Drug: Sulfadiazine
Outcome Measures: Persistent motor abnormality;   Vision;   Hearing;   New chorioretinal lesion;   IQ less than 70;   Decrease in IQ of greater than or equal to 15 points
4 Recruiting SPK Study in Afghanistan
Condition: Uncomplicated P. Falciparum Malaria
Intervention: Drug: Artesunate + Sulphadoxine-pyrimethamine
Outcome Measures: Adequate clinical and parasitological response (ACPR);   Adverse events;   Molecular markers for antimalarial drug resistance
5 Recruiting Evaluation of SP Resistance and Effectiveness of IPTp in Nigeria
Condition: Pregnancy Complications Parasitic
Intervention: Drug: Efficacy of suphladoxine/pyrimethamine as IPTp
Outcome Measures: To determine the efficacy of SP-IPTp for clearing peripheral malaria parasiteamia in asymptomatic primi and secondi gravid women;   To determine the efficacy of SP-IPTp in preventing new infections in primi- and secundi-gravid women;   To estimate the prevalence of molecular markers of SP resistance in primi- and secundi-gravid women
6 Not yet recruiting Efficacy of Antifolates Against Malaria in HIV-infected Pregnant Women and the Emergence of Induced Resistance in Plasmodium Falciparum
Conditions: Malaria in Pregnancy;   HIV Infection
Interventions: Drug: cotrimoxazole daily prophylaxis;   Drug: sulphadoxine-pyrimethamine
Outcome Measures: placental parasitaemia;   observance CTM prophylaxis;   occurrence of specific events related to the effectiveness of CTM prophylaxis and IPT-SP;   occurence of adverse events
7 Recruiting Chloroquine for Malaria in Pregnancy
Condition: Malaria
Interventions: Drug: sulfadoxine/pyrimethamine;   Drug: Chloroquine
Outcome Measures: Incidence of placental malaria infection based on histology.;   Incidence of low birth weight (LBW) (birthweight < 2500 grams);   Incidence of intrauterine growth restriction (IUGR) (weight <10th percentile gestational age based on the World Health Organization (WHO) fetal growth curve);   Incidence of placental malaria infection diagnosed by placental impression smear.;   Per arm: Incidence of clinical malaria, all species.;   Per arm: Incidence of malaria infection, all species.;   Incidence of active placental malaria infection diagnosed by the presence of parasites and/or pigment on histological section.;   Infant mortality rate to 14 weeks of age;   Incidence of preterm delivery;   Incidence of miscarriage (estimated gestational age <28 weeks);   Incidence of stillbirth;   Incidence of maternal severe anemia (hemoglobin < 7gm/dl);   Incidence of maternal anemia (hemoglobin < 10gm/dl);   Incidence of infection in the fetal circulation based on the results of the thick smear and polymerase chain reaction (PCR) from the cord blood sample.
8 Not yet recruiting Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants
Condition: Malaria
Interventions: Drug: Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy;   Drug: 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy;   Drug: 3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy;   Drug: Monthly dihydroartemisinin-piperaquine (DP) for infants;   Drug: 3-monthly dihydroartemisinin-piperaquine (DP) for infants
Outcome Measures: Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria.;   Incidence of malaria defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days.;   Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days;   Placental parasitemia;   Prevalence of maternal malaria;   Composite birth outcome;   Incidence of adverse events in pregnant women and infants;   Prevalence of anemia in pregnant women and infants;   Prevalence of asymptomatic parasitemia in pregnant women and infants;   Incidence of complicated malaria in infants;   Incidence of hospital admissions in infants;   Prevalence of gametocytemia in pregnant women and infants
9 Unknown  A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
Conditions: Uncomplicated Falciparum Malaria;   Vivax Malaria
Interventions: Drug: Dihydroartemisinin + Piperaquine (Artekin);   Drug: artesunate-sulphadoxin/pyrimethamine, chloroquine
Outcome Measures: PCR corrected adequate clinical and parasitological response (PCR corrected 'adequate clinical and parasitological response' or ACPR);   Crude or PCR uncorrected ACPR;   Early treatment failure (failure to clear parasitaemia);   fever clearance times;   parasite clearance times with no recrudescence over the observation period;   gametocyte clearance times;   Haemoglobin levels on day 14 compared to admission;   safety and tolerability (rate and severity of adverse events)
10 Recruiting Seasonal Malaria Chemoprevention Versus Home Management of Malaria in Children Under 5 Years in Ghana
Conditions: Malaria;   Anaemia
Interventions: Drug: Artemether-lumefantrine combination;   Drug: Dihydroartemisinin Piperaquine combination;   Drug: Amodiaquine plus sulphadoxine-pyrimethamine combination
Outcome Measures: Incidence of malaria cases;   Proportion of children with parasitaemia;   Proportion of children with anaemia;   Number of referrals;   Incidence of severe illness;   Incidence of adverse events
11 Unknown  Malarial Immunity in Pregnant Cameroonian Women
Condition: Plasmodium Falciparum Malaria
Outcome Measure:
12 Recruiting Assessment of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis
Condition: Congenital Toxoplasmosis
Interventions: Procedure: reducing treatment to 3 months;   Procedure: registered length of treatment
Outcome Measure: episode of retinochoroiditis
13 Recruiting Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A
Condition: Malaria
Interventions: Drug: Artemether-lumefantrine;   Drug: Dihydroartemisinin-piperaquine
Outcome Measures: Adequate clinical and parasitological response rate;   the safety of AL and DP

These studies may lead to new treatments and are adding insight into Malocide etiology and treatment.

A major focus of Malocide research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Malocide